Glaxosmithkline Biologicals Sa

Marcelle Paulette Van Mechelen

Jan Poolman

Ralph Leon Biemans

Philippe Vincent Hermand

Nathalie Marie-Josephe Garcon

Nathalie Marie-Josephe Garçon

The present invention is in the field of pneumococcal capsular saccharide conjugate vaccines. Specifically, an immunogenic composition for infants is provided comprising a multivalentvaccine comprising 2 or more capsular saccharide conjugates from different serotypes, wherein the composition comprises a serotype 22F saccharide conjugate. Such a vaccine may be used in infant populations to reduce the incidence of elderly pneumococcal disease such as exacerbations of COPD and/or IPD.

Pneumococcal capsular saccharide conjugate vaccine

The present invention discloses an immunogenic composition comprisingcapsular saccharide conjugates from serotypes 19A and 19F wherein 19A is conjugated to a first bacterial toxoid and 19F is conjugated to a second bacterial toxoid. Vaccines, methods of making vaccines and uses of the vaccines are also described.

Vaccine

[object Object]

The present invention is in the field of pneumococcal capsular saccharide conjugate vaccines. Specifically, a multivalentimmunogenic composition is provided with various conjugated capsular saccharides from differentserotypes conjugated to 2 or more different carrier proteins, where the composition comprises serotype 19F capsular saccharide conjugated to diphtheria toxoid (DT) or CRM197, optionally wherein 19F is the only saccharide in the composition conjugated to diphtheria toxoid (DT) or CRM197.

Pneumoccal polysacchride conjugate vaccine

The present invention relates to an immunogenic composition comprisingcapsular saccharide conjugates from serotypes 19A and 19F wherein 19A is conjugated to a first bacterial toxoid and 19F is conjugated to a second bacterial toxoid. Methods of making and uses thereof are also described.

Growing community of inventors

Rixensart, Belgium

Marcelle Paulette Van Mechelen